Ascendis Pharma A/S develops TransCon therapies, which are prodrug therapies designed to address various medical conditions. The company has multiple product candidates in clinical trials, including treatments for Turner syndrome, idiopathic short stature, achondroplasia, and adult hypoparathyroidism. Its clinical programs are conducted in various countries, with a focus on improving patient outcomes across different age groups.
